Latest Conference Articles

March 8th 2014, 9:00am

PER® Miami Breast Cancer Conference

The US Supreme Court's landmark decision last June, mandating that an individual's genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.

March 8th 2014, 8:19am

PER® Miami Breast Cancer Conference

The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.

March 7th 2014, 12:47pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.

March 7th 2014, 12:44pm

PER® Miami Breast Cancer Conference

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses surgical resection of the primary breast tumor in patients with stage IV breast cancer.

March 7th 2014, 9:54am

PER® Miami Breast Cancer Conference

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

March 7th 2014, 8:59am

PER® Miami Breast Cancer Conference

Over the past few decades, the optimal margin width for minimizing recurrence after breast-conserving surgery (BCS; lumpectomy) has been a topic of much debate

March 7th 2014, 8:27am

PER® Miami Breast Cancer Conference

The large Canadian study that has caused a stir by indicating that mammograms are of no use in women aged 40 to 59 years, and in fact can lead to over-diagnosis of breast cancer, is flawed and misleading

March 6th 2014, 3:46pm

PER® Miami Breast Cancer Conference

Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, describes oncoplastic surgery.

March 6th 2014, 12:35pm

PER® Miami Breast Cancer Conference

Hyman B. Muss, MD, discusses optimizing the administration of endocrine therapies with or without mTOR inhibitors for patients with HR-positive metastatic breast cancer

February 3rd 2014, 12:36pm

Genitourinary Cancers Symposium (ASCO GU)

Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

February 3rd 2014, 11:05am

Genitourinary Cancers Symposium (ASCO GU)

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

February 3rd 2014, 10:22am

Genitourinary Cancers Symposium (ASCO GU)

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

February 1st 2014, 11:13am

Genitourinary Cancers Symposium (ASCO GU)

Two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.

February 1st 2014, 11:04am

Genitourinary Cancers Symposium (ASCO GU)

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

February 1st 2014, 10:08am

Genitourinary Cancers Symposium (ASCO GU)

Survival, measured as either disease-specific survival or relative conditional survival, has not improved for patients with metastatic urothelial carcinoma despite increasing use of second-line therapies with no formal indication in this setting.

February 1st 2014, 9:06am

Genitourinary Cancers Symposium (ASCO GU)

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses validating a whole-blood RNA prognostic signature in mCRPC.

January 31st 2014, 4:44pm

Genitourinary Cancers Symposium (ASCO GU)

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer, does not raise the risk for severe toxicities, nor does it affect overall survival.

January 31st 2014, 11:07am

Genitourinary Cancers Symposium (ASCO GU)

Patients with metastatic castration-resistant prostate cancer (mCRPC) who have detectable serum androgen levels despite treatment with ketoconazole experience prostate-specific antigen (PSA) response to subsequent abiraterone acetate

January 31st 2014, 9:25am

Genitourinary Cancers Symposium (ASCO GU)

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.

January 31st 2014, 8:32am

Genitourinary Cancers Symposium (ASCO GU)

Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.